Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers
Drug Resistance Updates · 2024-03 · 73 · 101042
DOI: 10.1016/j.drup.2023.101042 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2024-03. Verfasst von Yuanfang Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer,Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: NF-kappa B, Neoplasms. Die Arbeit wurde bisher 136-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Drug resistance in cancer remains a major challenge in oncology, impeding the effectiveness of various treatment modalities. The nuclear factor-kappa B (NF-κB) signaling pathway has emerged as a critical player in the development of drug resistance in cancer cells. This comprehensive review explores the intricate relationship between NF-κB and drug resistance in cancer. We delve into the molecular mechanisms through which NF-κB activation contributes to resistance against chemotherapeutic agents, targeted therapies, and immunotherapies. Additionally, we discuss potential strategies to overcome this resistance by targeting NF-κB signaling, such as small molecule inhibitors and combination therapies. Understanding the multifaceted interactions between NF-κB and drug resistance is crucial for the development of more effective cancer treatment strategies. By dissecting the complex signaling network of NF-κB, we hope to shed light on novel therapeutic approaches that can enhance treatment outcomes, ultimately improving the prognosis for cancer patients. This review aims to provide a comprehensive overview of the current state of knowledge on NF-κB and its role in drug resistance, offering insights that may guide future research and therapeutic interventions in the fight against cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer,Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
- Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen 518107, China.
- School of Medicine, Sun Yat-sen University, China.
- The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China.
- The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China. Electronic address: 1995020005@usc.edu.cn.
- The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China. Electronic address: 2018012078@usc.edu.cn.
Zitieren
APA
Li, Y., Zhao, B., Peng, J., Tang, H., Wang, S., Peng, S., Ye, F., Wang, J., Ouyang, K., Li, J., Cai, M., & Chen, Y. (2024). Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers. Drug Resistance Updates, 73, 101042. https://doi.org/10.1016/j.drup.2023.101042
Vancouver
Li Y, Zhao B, Peng J, Tang H, Wang S, Peng S, et al. Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers. Drug Resistance Updates. 2024;73:101042. doi:10.1016/j.drup.2023.101042
BibTeX
@article{Li2024,
author = {Li, Yuanfang and Zhao, Baiwei and Peng, Juzheng and Tang, Hailin and Wang, Sicheng and Peng, Sicheng and Ye, Feng and Wang, Junye and Ouyang, Kai and Li, Jianjun and Cai, Manbo and Chen, Yongming},
title = {Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers},
journal = {Drug Resistance Updates},
year = {2024},
volume = {73},
pages = {101042},
doi = {10.1016/j.drup.2023.101042}
}
EUVIMED